FIELD: medicine.
SUBSTANCE: invention relates to immunology and biotechnology. Claimed is an application of Fc region with mutation 434S and 428L for increasing the period of half-life in vivo of a polypeptide, which contains the said region.
EFFECT: application of the invention provides the increased time of half-life of the antibody with the said Fc region, which can be applied in medicine for obtaining different constructions of antibodies with the prolonged time of retention in blood serum in vivo.
2 cl, 22 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VARIANTS OF Fc WITH CHANGED BINDING WITH FcRn | 2014 |
|
RU2700882C2 |
| Fc-VERSIONS WITH ALTERED BINDING WITH FcRn | 2008 |
|
RU2517621C2 |
| DESIGNED IL-2-FC FUSION PROTEINS | 2018 |
|
RU2812283C2 |
| Fc-VERSIONS WITH CHANGED BINDING WITH FcRn | 2005 |
|
RU2412200C2 |
| VERSIONS OF IMMUNOGLOBULIN AND THEIR APPLICATION | 2009 |
|
RU2536937C2 |
| POLYPEPTIDE VARIANTS WITH CHANGED EFFECTOR FUNCTION | 2005 |
|
RU2367667C2 |
| Fc-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE | 2014 |
|
RU2687043C2 |
| AFFINITY CHROMATOGRAPHY WITH APPLICATION OF Fc-RECEPTORS | 2013 |
|
RU2624128C2 |
| VARIANTS WITH Fc-FRAGMENT, HAVING HIGH AFFINITY TO FcRn AND HIGH AFFINITY TO AT LEAST ONE RECEPTOR OF Fc-FRAGMENT | 2018 |
|
RU2820162C2 |
| OPTIMIZED Fc-VERSIONS THAT HAVE ALTERED BINDING TO FcγR AND METHODS FOR THEIR PRODUCTION | 2004 |
|
RU2337107C2 |
